Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG)

H S Park,B Kang,H J Chon,H-S Im,C-K Lee,I Kim, M J Kang,J E Hwang, W K Bae,J Cheon, J O Park,J Y Hong, J H Kang,J H Kim, S H Lim,J W Kim,J-W Kim,C Yoo,H J Choi

ESMO Open（2021）

引用 23|浏览15

暂无评分

摘要

•This multicenter retrospective study investigated nal-IRI/FL and FOLFIRINOX outcomes after gemcitabine-based therapy.•We found no significant differences in outcome between nal-IRI/FL and FOLFIRINOX treatment.•Both regimens were well tolerated; however, neutropenia and peripheral neuropathy were more frequent with FOLFIRINOX.•Age (cut-off, 70 years) showed differential efficacy between chemotherapy regimens.

查看译文

关键词

pancreatic cancer,second-line treatment,liposomal irinotecan,FOLFIRINOX

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要